Pheochromocytoma and paraganglioma: Recent progress and new vistas for improved patient care

Hormone and Metabolic Research

Volumn 44, Issue 5, 2012, Pages 325-327

  Eisenhofer, G ^a   Schott, M ^b   Bornstein, S ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN DERIVATIVE;

CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; GENETIC SUSCEPTIBILITY; HUMAN; PARAGANGLIOMA; PATIENT CARE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY;

ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA; PATIENT CARE; PHEOCHROMOCYTOMA;

EID: 84858706937     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1299759     Document Type: Conference Paper

References (23)

1. Gimenez-Roqueplo A P, Tischler A S. Pheochromocytoma and Paraganglioma: Progress on all fronts. Endocr Pathol: 2012; 23 1 3
2. Gimenez-Roqueplo A P, Dahia P L, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res: 2012; 44 328 333
3. Qin Y, Yao L, King E E, Buddavarapu K, Lenci R E, Chocron E S, Lechleiter J D, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo R A, Toledo S P, Stiles C, Aguiar R C, Dahia P L. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet: 2010; 42 229 233
4. Comino-Mndez I, Gracia-Aznrez F J, Schiavi F, Landa I, Leandro-Garca L J, Letn R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gmez-Graa A, de Cubas A A, Inglada-Prez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernndez-Lavado R, Daz J A, Gmez-Morales M, Gonzlez-Neira A, Roncador G, Rodrguez-Antona C, Bentez J, Mannelli M, Opocher G, Robledo M, Cascn A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genet: 2011; 43 663 667
5. Lefebvre S, Borson-Chazot F, Boutry-Kryza N, Wion N, Schillo F, Peix J L, Brunaud L, Finat A, Calender A, Giraud S. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. Horm Metab Res: 2012; 44 334 338
6. Persu A, Lannoy N, Maiter D, Mendola A, Montigny P, Oriot P, Vinck W, Garin P, Hamoir M, Vikkula M. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update. Horm Metab Res: 2012; 44 349 353
7. Elston M S, Meyer-Rochow G Y, Holdaway I, Conaglen J V. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma. Horm Metab Res: 2012; 44 339 342
8. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M, Travers C, Simian C, Burnichon N, Abermil N, Favier J, Jeunemaitre X, Gimenez-Roqueplo A P. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res: 2012; 44 359 366
9. Lahlou-Laforet K, Consoli S M, Jeunemaitre X, Gimenez-Roqueplo A P. Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation. Horm Metab Res: 2012; 44 354 358
10. Eisenhofer G, Vocke C D, Elkahloun A, Huynh T T, Prodanov T, Lenders J W, Timmers H J, Benhammou J N, Linehan W M, Pacak K. Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicates a need for caution. Horm Metab Res: 2012; 44 343 348
11. Eisenhofer G, Lenders J W, Siegert G, Bornstein S R, Friberg P, Milosevic D, Mannelli M, Linehan W M, Adams K, Timmers H, Pacak K. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumor size, location and SDHB mutation status. Eur J Cancer: 2011; Oct 28 [Epub ahead of print]
12. Amar L, Fassnacht M, Gimenez-Roqueplo A P, Januszewicz A, Prejbisz A, Timmers H, Plouin P F. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res: 2012; 44 385 389
13. Plouin P F, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier N, Baudin E, Jimenez C. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res: 2012; 44 390 399
14. Eisenhofer G, Tischler A S, de Krijger R. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: From routine laboratory methods to disease stratification. Endocr Pathol: 2012; 23 4 14
15. Timmers H J, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res: 2012; 44 367 372
16. Spetz J, Dalmo J, Nilsson O, Wängberg B, Ahlman H, Forssell-Aronsson E. Specific binding and uptake of 131I-MIBG and 111In-octreotide in malignant paraganglioma - tools for choice of radionuclide therapy. Horm Metab Res: 2012; 44 400 404
17. 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res: 2012; 44 411 414
18. Fishbein L, Bonner L, Torigian D A, Nathanson K L, Cohen D L, Pryma D, Cengel K A. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm Metab Res: 2012; 44 405 410
19. Cascon A, Tennant D A. From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma. Endocr Pathol: 2012; 23 15 20
20. Bayley J P, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev: 2010; 20 324 329
21. Favier J, Igaz P, Burnichon N, Amar L, Libe R, Badoual C, Tissier F, Bertherat J, Plouin P F, Jeunemaitre X, Gimenez-Roqueplo A P. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol: 2012; 23 34 42
22. Nölting S, Grossman A. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol: 2012; 23 21 33
23. Korpershoek E, Pacak K, Martiniova L. Murine models and cell lines for the investigation of pheochromocytoma: Applications for future therapies. Endocr Pathol: 2012; 23 43 54